|1.||Vitti, Robert: 17 articles (10/2015 - 06/2011)|
|2.||Berliner, Alyson J: 17 articles (10/2015 - 11/2009)|
|3.||Heier, Jeffrey S: 13 articles (10/2015 - 06/2011)|
|4.||Brown, David M: 13 articles (10/2015 - 06/2011)|
|5.||Zeitz, Oliver: 12 articles (10/2015 - 05/2012)|
|6.||Kaiser, Peter K: 12 articles (10/2015 - 03/2012)|
|7.||Schmidt-Erfurth, Ursula: 11 articles (10/2015 - 09/2011)|
|8.||Do, Diana V: 10 articles (01/2016 - 11/2009)|
|9.||Sandbrink, Rupert: 10 articles (04/2015 - 09/2011)|
|10.||Nguyen, Quan Dong: 9 articles (01/2016 - 11/2009)|
|1.||Macular Degeneration (Age-Related Maculopathy)
03/01/2015 - "Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration."
12/01/2015 - "To prospectively assess the safety and efficacy of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD). "
10/01/2015 - "Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). "
05/01/2015 - "To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings. "
01/01/2015 - "In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2012 - "Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. "
05/01/2015 - "[Sequential inhibition of angiogenesis in metastatic colorectal cancer: activity and efficacy of aflibercept]."
11/01/2014 - "Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer."
11/01/2012 - "We assessed the safety and efficacy of aflibercept in patients with metastatic colorectal cancer (MCRC) who had received at least one prior palliative regimen. "
09/29/2015 - "Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting."
11/01/2014 - "Patients with macular edema following CRVO benefited from early treatment with intravitreal aflibercept."
10/01/2015 - "Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies."
03/01/2015 - "Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study."
11/01/2014 - "Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study."
07/01/2014 - "Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study."
06/01/2015 - "Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study."
08/01/2012 - "Preclinical ophthalmologic studies demonstrated that aflibercept suppresses choroidal neovascularization in several animal models. "
06/01/2015 - "To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal neovascularization (CNV). "
01/01/2013 - "The availability of agents with alternative molecular structures, such as aflibercept, may permit additional insights into the complex relationship between choroidal neovascularization, vitritis, and innate and other immunologic processes."
12/01/2012 - "In this double-masked, phase 1 study, 28 patients with lesions ≤12 disc areas, ≥50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) ≤20/40 were randomized 1:1 to a single intravitreal injection of aflibercept 0.15 or 4 mg. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2012 - "Results from the phase III study, VITAL, of aflibercept in the second-line setting in patients with advanced non-small cell lung cancer [NCT00532155] demonstrated efficacy in progression-free survival and overall objective response rate, but overall survival was not significantly improved. "
02/04/2014 - "This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). "
02/04/2014 - "A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer."
10/10/2012 - "Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial."
01/01/2013 - "The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. "
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||salicylhydroxamic acid (SHAM)
|3.||Drug Therapy (Chemotherapy)